About APAC Biotech
APAC Biotech is a company based in Gurugram (India) founded in 2010. APAC Biotech has raised $991.24 thousand across 1 funding round from investors including Projects Development. APAC Biotech offers products and services including APCEDEN® and LTR-Memvaxraleucel™. APAC Biotech operates in a competitive market with competitors including NexImmune, eTheRNA, Argos Therapeutics, Northwest Biotherapeutics and Dendreon, among others.
- Headquarter Gurugram, India
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Apac Biotech Private Limited
- Date of Incorporation 21 Dec, 2010
- Jurisdiction Delhi, India
-
Annual Revenue
$139.35 K (USD)20.87as on Mar 31, 2023
-
Net Profit
-$375.85 K (USD)-94.76as on Mar 31, 2023
-
EBITDA
-$88.52 K (USD)18.89as on Mar 31, 2023
-
Total Equity Funding
$991.24 K (USD)
in 1 rounds
-
Latest Funding Round
$991.24 K (USD), Seed
Mar 31, 2011
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of APAC Biotech
APAC Biotech offers a comprehensive portfolio of products and services, including APCEDEN® and LTR-Memvaxraleucel™.
Personalized dendritic cell therapy to enhance immune response against cancer.
Reprograms immune cells to treat cancer like a viral infection.
Funding Insights of APAC Biotech
APAC Biotech has successfully raised a total of $991.24K through 1 strategic funding round. The most recent funding activity was a Seed round of $991.24 thousand completed in March 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in APAC Biotech
APAC Biotech has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Projects Development.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Develops residential and commercial projects with innovative designs in Lebanon.
|
Locked | Locked | Locked |
Investor details for APAC Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by APAC Biotech
Investment portfolio details for APAC Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - APAC Biotech
Detailed financials for APAC Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Apac Biotech Comparisons
Peer comparison for APAC Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of APAC Biotech
APAC Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NexImmune, eTheRNA, Argos Therapeutics, Northwest Biotherapeutics and Dendreon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Immunotherapeutics for cancer, diabetes, and viral diseases are developed.
|
|
| Locked | Locked | Locked |
mRNA-based immunotherapies for cancer and infectious diseases are developed.
|
|
| Locked | Locked | Locked |
An online gambling platform is operated for Tai Xiu games.
|
|
| Locked | Locked | Locked |
Dendritic cell-based vaccines for prostate and brain cancers are developed.
|
|
| Locked | Locked | Locked |
Autologous dendritic cell immunotherapies are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Dendritic cell immunotherapies for mesothelioma and other cancers are developed.
|
Detailed competitors of APAC Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Apac Biotech
Complete news archive for APAC Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about APAC Biotech
APAC Biotech was founded in 2010 and raised its 1st funding round 1 year after it was founded.
APAC Biotech is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.
Arun Mehra is the current CEO of APAC Biotech.
APAC Biotech is a funded company, having raised a total of $991.24K across 1 funding round to date.
Annual revenue of APAC Biotech is $139.35K as on Mar 31, 2023.
APAC Biotech was founded in 2010 in Gurugram, India, within the biotechnology sector. Focus is placed on developing autologous monocyte-derived dendritic cell immunotherapy for various cancers. The primary therapy, Apceden, employs patients own monocytes to target cancer-specific dendritic cells. Treatments have been established for colorectal cancer, non-small cell lung carcinoma, ovarian carcinoma, and prostate cancer. Ongoing development targets glioblastoma multiforme and renal cancer.
APAC Biotech's top competitors include eTheRNA, NexImmune and Argos Therapeutics.
APAC Biotech offers APCEDEN® and LTR-Memvaxraleucel™.
APAC Biotech has 1 investor. Key investors include Projects Development.
The valuation of APAC Biotech is $4.03M as of Mar 2011.